Sept 12 (Reuters) - Zenas BioPharma, which is developing

immunology-based therapies, said on Thursday it has raised $225

million in its U.S. initial public offering.

The clinical-stage company, backed by drugmaker

Bristol-Myers Squibb ( BMY ), priced its offering of 13.2

million shares at $17 each, midpoint of its targeted range of

$16 to $18 per share.